The PT-141 dosage women use per the FDA label is 1.75 mg under the skin, up to 8 doses a month. See compounded, nasal spray, and calculator guidance.
The short answer is 1.75 mg, injected under the skin, at least 45 minutes before sexual activity and no more than once in 24 hours. That figure comes from Vyleesi, the only bremelanotide product the FDA has approved for human use. Published guidance on pt-141 for women dosage stays narrow because compounded PT-141 sold online is not FDA-approved, and its dosing is set by whoever mixed the vial rather than by a federal label.
What the FDA-Approved PT-141 Dose for Women Actually Is
Vyleesi (bremelanotide) is a subcutaneous autoinjector first approved in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The label specifies one fixed dose, with no weight-based adjustment and no titration step.
| Label detail | Vyleesi (bremelanotide) 1.75 mg |
|---|---|
| Dose | 1.75 mg (0.3 mL) per injection |
| Route | Subcutaneous, abdomen or thigh |
| Timing | At least 45 minutes before anticipated sexual activity |
| Maximum frequency | One dose per 24 hours |
| Monthly limit | No more than 8 doses per month |
| Approved group | Premenopausal women with HSDD |
Two limits matter as much as the dose itself. Women should not exceed one dose in 24 hours or eight doses in a month. The label ties those caps to a higher risk of blood pressure increases and skin darkening with more frequent use.
Why Compounded PT-141 Doses Vary So Much
Most PT-141 sold outside pharmacies is a lyophilized powder that the buyer reconstitutes with bacteriostatic water. Because the amount of diluent is chosen by the seller or the user, two identical "10 mg vials" can end up at very different strengths.
People who search for pt-141 10mg dosage women are usually looking at exactly this kind of vial, and there is no single correct answer for them. A 10 mg vial is a container size, not a dose — it holds roughly 5.7 times the FDA-approved amount.
| Vial size | Diluent added | Concentration | Volume for 1.75 mg |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 0.175 mL |
| 10 mg | 2 mL | 5 mg/mL | 0.35 mL |
| 10 mg | 3 mL | 3.33 mg/mL | 0.525 mL |
This is also why two people can inject the same number of "units" and receive completely different amounts of drug. Concentration, not volume, determines the dose.
Using a PT-141 Dosage Calculator for Women
A pt-141 dosage calculator for women converts a target dose in milligrams into a volume in milliliters or syringe units. The math is simple, but it only works when the concentration printed on the vial is accurate.
- Confirm the concentration in mg/mL after reconstitution.
- Divide the target dose by the concentration to get milliliters.
- Convert milliliters to units on a U-100 insulin syringe (1 mL = 100 units).
- Verify the result with a second method before drawing up a dose.
A 1.75 mg dose drawn from a 5 mg/mL solution equals 0.35 mL, or 35 units on a U-100 syringe. If the math tells you to inject more than about 1 mL under the skin in one sitting, the concentration is almost certainly wrong.
PT-141 Nasal Spray Dosage for Women
There is no FDA-approved pt-141 nasal spray dosage for women, and no manufacturer label exists for that route. Nasal products sold online are unregulated, and how much peptide crosses the nasal lining varies widely between products and between users.
Early intranasal bremelanotide studies used total amounts well above the injected dose, often in the 7.5 mg to 20 mg range. Those trials relied on standardized spray devices made by the drug's developer, which is not what a gray-market spray bottle delivers.
PT-141 Dosage for Women Side Effects
The most commonly reported pt-141 dosage for women side effects in clinical trials were nausea, flushing, headache, and injection-site reactions. Nausea was the single most frequent reason participants stopped using the drug.
Two less obvious risks are worth knowing before you dose:
- Blood pressure. Bremelanotide causes a temporary rise in blood pressure that peaks about two hours after injection. It is not recommended for women with uncontrolled hypertension or known cardiovascular disease.
- Hyperpigmentation. Darkening of the gums, face, or breasts has been reported, and the risk appears to climb with more frequent dosing.
Compounded versions carry the same underlying risks plus additional ones: inaccurate concentration, contamination, or a different peptide in the vial.
Is There an Approved PT-141 Dose for Men?
No. Bremelanotide is not FDA-approved for men, and no official male dosing exists. Vendors frequently publish a "men's protocol" next to the female one, but those numbers come from small early studies or from the sellers themselves.
The same caution applies to other off-label uses, including use by postmenopausal women. Anyone considering PT-141 outside the approved indication should speak with a clinician rather than copy a protocol from a product page.
Safety, Legality, and Questions to Ask a Clinician
Bremelanotide is a prescription medication in the United States, and buying it without a prescription is illegal. Independent testing of compounded peptides has repeatedly found wrong concentrations and unlisted substances.
If you are considering PT-141, these are reasonable questions for a healthcare professional:
- Is my blood pressure in a range where this medication is safe?
- Do any of my current medications interact with bremelanotide?
- What should I do if the first few doses do not work?
- Is the product I am being offered FDA-approved or compounded?
PT-141 is not a hormone and does not work like testosterone or estrogen. It acts on melanocortin receptors in the brain and is designed to be used on demand, not as a daily supplement.
Frequently Asked Questions
How much PT-141 should a woman take?
The FDA-approved bremelanotide dose is 1.75 mg injected subcutaneously, no more than once every 24 hours and no more than 8 times per month. Compounded PT-141 has no approved dose, so anyone using it should work with a healthcare professional rather than guessing.
Can a woman use a 10 mg PT-141 vial?
A 10 mg vial is a container size, not a dose, and it holds about 5.7 times the FDA-approved 1.75 mg amount. The actual dose depends entirely on how much diluent was added, so the concentration must be calculated before any injection.
How long before sex should a woman inject PT-141?
The label directs women to inject at least 45 minutes before anticipated sexual activity, and the effect can last a few hours afterward. Doses should not be repeated within the same 24-hour period.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.